These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19402024)

  • 1. Mutagenesis and molecular modeling of the orthosteric binding site of the mGlu2 receptor determining interactions of the group II receptor antagonist (3)H-HYDIA.
    Lundström L; Kuhn B; Beck J; Borroni E; Wettstein JG; Woltering TJ; Gatti S
    ChemMedChem; 2009 Jul; 4(7):1086-94. PubMed ID: 19402024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymmetric synthesis and receptor pharmacology of the group II mGlu receptor ligand (1S,2R,3R,5R,6S)-2-amino-3-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid-HYDIA.
    Woltering TJ; Adam G; Huguenin P; Wichmann J; Kolczewski S; Gatti S; Bourson A; Kew JN; Richards G; Kemp JA; Mutel V; Knoflach F
    ChemMedChem; 2008 Feb; 3(2):323-35. PubMed ID: 18058780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.
    Monn JA; Prieto L; Taboada L; Hao J; Reinhard MR; Henry SS; Beadle CD; Walton L; Man T; Rudyk H; Clark B; Tupper D; Baker SR; Lamas C; Montero C; Marcos A; Blanco J; Bures M; Clawson DK; Atwell S; Lu F; Wang J; Russell M; Heinz BA; Wang X; Carter JH; Getman BG; Catlow JT; Swanson S; Johnson BG; Shaw DB; McKinzie DL
    J Med Chem; 2015 Sep; 58(18):7526-48. PubMed ID: 26313429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.
    Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S
    Neuropharmacology; 2016 Dec; 111():253-265. PubMed ID: 27590915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reprint of Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.
    Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S
    Neuropharmacology; 2017 Mar; 115():115-127. PubMed ID: 28216000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
    J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain structures.
    Monn JA; Prieto L; Taboada L; Pedregal C; Hao J; Reinhard MR; Henry SS; Goldsmith PJ; Beadle CD; Walton L; Man T; Rudyk H; Clark B; Tupper D; Baker SR; Lamas C; Montero C; Marcos A; Blanco J; Bures M; Clawson DK; Atwell S; Lu F; Wang J; Russell M; Heinz BA; Wang X; Carter JH; Xiang C; Catlow JT; Swanson S; Sanger H; Broad LM; Johnson MP; Knopp KL; Simmons RM; Johnson BG; Shaw DB; McKinzie DL
    J Med Chem; 2015 Feb; 58(4):1776-94. PubMed ID: 25602126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
    Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
    J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of essential residues involved in the glutamate binding pocket of the group II metabotropic glutamate receptor.
    Malherbe P; Knoflach F; Broger C; Ohresser S; Kratzeisen C; Adam G; Stadler H; Kemp JA; Mutel V
    Mol Pharmacol; 2001 Nov; 60(5):944-54. PubMed ID: 11641422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biology of the conformationally restricted ACPD analogue, 2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid-I, a potent mGluR agonist.
    Kozikowski AP; Steensma D; Araldi GL; Tückmantel W; Wang S; Pshenichkin S; Surina E; Wroblewski JT
    J Med Chem; 1998 May; 41(10):1641-50. PubMed ID: 9572889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist.
    Dominguez C; Prieto L; Valli MJ; Massey SM; Bures M; Wright RA; Johnson BG; Andis SL; Kingston A; Schoepp DD; Monn JA
    J Med Chem; 2005 May; 48(10):3605-12. PubMed ID: 15887967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
    Marek GJ; Wright RA; Schoepp DD; Monn JA; Aghajanian GK
    J Pharmacol Exp Ther; 2000 Jan; 292(1):76-87. PubMed ID: 10604933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists.
    Koike H; Iijima M; Chaki S
    Neuropharmacology; 2011 Dec; 61(8):1419-23. PubMed ID: 21903115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.
    Chappell MD; Li R; Smith SC; Dressman BA; Tromiczak EG; Tripp AE; Blanco MJ; Vetman T; Quimby SJ; Matt J; Britton TC; Fivush AM; Schkeryantz JM; Mayhugh D; Erickson JA; Bures MG; Jaramillo C; Carpintero M; Diego JE; Barberis M; Garcia-Cerrada S; Soriano JF; Antonysamy S; Atwell S; MacEwan I; Condon B; Sougias C; Wang J; Zhang A; Conners K; Groshong C; Wasserman SR; Koss JW; Witkin JM; Li X; Overshiner C; Wafford KA; Seidel W; Wang XS; Heinz BA; Swanson S; Catlow JT; Bedwell DW; Monn JA; Mitch CH; Ornstein PL
    J Med Chem; 2016 Dec; 59(24):10974-10993. PubMed ID: 28002967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists.
    Nakazato A; Kumagai T; Sakagami K; Yoshikawa R; Suzuki Y; Chaki S; Ito H; Taguchi T; Nakanishi S; Okuyama S
    J Med Chem; 2000 Dec; 43(25):4893-909. PubMed ID: 11123999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators.
    Lundström L; Bissantz C; Beck J; Wettstein JG; Woltering TJ; Wichmann J; Gatti S
    Br J Pharmacol; 2011 Sep; 164(2b):521-37. PubMed ID: 21470207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu
    Witkin JM; Ornstein PL; Mitch CH; Li R; Smith SC; Heinz BA; Wang XS; Xiang C; Carter JH; Anderson WH; Li X; Broad LM; Pasqui F; Fitzjohn SM; Sanger HE; Smith JL; Catlow J; Swanson S; Monn JA
    Neuropharmacology; 2017 Mar; 115():100-114. PubMed ID: 26748052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular modeling and mutagenesis of the ligand-binding pocket of the mGlu3 subtype of metabotropic glutamate receptor.
    Yao Y; Pattabiraman N; Michne WF; Huang XP; Hampson DR
    J Neurochem; 2003 Aug; 86(4):947-57. PubMed ID: 12887692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors.
    Schweitzer C; Kratzeisen C; Adam G; Lundstrom K; Malherbe P; Ohresser S; Stadler H; Wichmann J; Woltering T; Mutel V
    Neuropharmacology; 2000 Jul; 39(10):1700-6. PubMed ID: 10884552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of allosteric modulation: Exploring the binding kinetics of glutamate and other orthosteric ligands of the metabotropic glutamate receptor 2.
    Doornbos MLJ; Vermond SC; Lavreysen H; Tresadern G; IJzerman AP; Heitman LH
    Biochem Pharmacol; 2018 Sep; 155():356-365. PubMed ID: 30028996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.